{
}
UBS has maintained a 'Buy' rating for Merck KGaA, setting a target price of 190 euros following the release of quarterly figures. Analyst Matthew Weston noted that the key figures presented few surprises after the recent capital market day.
UBS AG has maintained a "Buy" rating for Merck KGaA, setting a target price of 190 euros following the latest quarterly figures. Despite a 1.2% decline in share price to EUR 144.70, there remains a potential upside of 31.31%. The company is set to release its Q4 2024 results on March 6, 2025.
UBS has maintained a "Buy" rating for Merck KGaA, setting a target price of 190 euros following the company's third-quarter results. While sales met market expectations, the adjusted EBITDA exceeded forecasts due to reduced research spending in the healthcare sector, although this trend may not continue. Overall, the results did not present any significant surprises.
UBS has reaffirmed its Buy rating for Novartis, setting a price target of 111 francs, following insights from a recent conference. CFO Harry Kirsch expressed optimism about growth prospects for 2025, coinciding with the expiration of the Entresto patent, according to analyst Matthew Weston.
UBS has maintained its 'Buy' rating for Novartis, setting a price target of 111 francs. CFO Harry Kirsch expressed optimism about the company's growth prospects for 2025, coinciding with the expiration of the Entresto patent, according to analyst Matthew Weston.
UBS AG has maintained a "Buy" rating for Merck KGaA, setting a target price of €190 following the third-quarter results, which met expectations. Despite a 1.8% drop in share price to €148.75, the stock shows a potential upside of 27.73%. The upcoming Q3 2024 figures are due on November 14, 2024.
UBS has maintained its "Buy" rating for Novartis, setting a price target of 111 francs, following insights from a recent conference. CFO Harry Kirsch expressed optimism about growth prospects for 2025, coinciding with the expiration of the Entresto patent, according to analyst Matthew Weston.
UBS has maintained its "Buy" rating for Merck KGaA, setting a target price of 190 euros following the third quarter results. Sales met market expectations, while the adjusted EBITDA exceeded forecasts due to reduced research spending in the healthcare sector, although this trend may not continue. Overall, the results did not present any significant surprises.
UBS AG has maintained a "Buy" rating for Merck KGaA, setting a target price of 190 euros following the third-quarter results. While sales met expectations, the adjusted EBITDA rose due to reduced research spending, though this trend may not continue. Merck shares fell 1.8% to EUR 148.75, indicating a potential upside of 27.73% relative to the target price.
UBS has maintained a "Neutral" rating for Roche shares with a target price of 270 francs, following insights from pharmaceuticals chief Teresa Graham. The shares rose 0.2% to CHF 262.90, reflecting a 12% increase since the start of 2024, with a 2.7% upside potential remaining. Q4 2024 results are set to be released on January 30, 2025.
Matthew Weston
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for merck kgaa with target price of 190 euros
10:46 15.11.2024
ubs maintains buy rating for merck with target price of 190 euros
10:37 15.11.2024
UBS maintains buy rating for Merck KGaA with target price of 190 euros
13:35 14.11.2024
UBS maintains buy rating for Novartis with price target of 111 francs
12:35 14.11.2024
ubs maintains buy rating for novartis with target of 111 francs
12:31 14.11.2024
ubs maintains buy rating for merck with target price of 190 euros
11:52 14.11.2024
UBS maintains buy rating for Novartis with price target of 111 francs
Swiss Franc
Novartis AG
UBS AG
CHE
Harry Kirsch
Matthew Weston
Hubert Dichtl
Thomas Müller
Show more
11:43 14.11.2024
UBS maintains buy rating for Merck KGaA with target price of 190 euros
11:02 14.11.2024
ubs maintains buy rating for merck with target price of 190 euros
10:52 14.11.2024
ubs maintains neutral rating for roche shares with target price of 270 francs
14:52 13.11.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Retail and Consumer Goods
Global Financial Events
Finance Mergers & Acquisitions
Global Trade Developments
Industry Mergers & Acquisitions
Central Bank Actions
CEO Changes
Banking Regulations
Supply Chain Management
Startups & Entrepreneurship
Energy Sector Developments
Government Economic Policies
Workplace Trends
AI Innovations
Cryptocurrency Trends
Market Analysis and Predictions
Financial Scams and Security
Countries:
Companies:
The Goldman Sachs Group, Inc.
Bank of America Corporation
Apple Inc.
Alphabet Inc.
Barclays PLC
Tesla, Inc.
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank RV Global PP
Commerzbank AG
Lloyds Banking Group plc
PepsiCo, Inc.
BNP Paribas SA
Google Inc.
NVIDIA Corporation
UBS Group AG
Wix.com Ltd.
BP Castrol K.K.
Valvoline Inc.
Bosch Limited
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Indonesian Rupiah
Canadian Dollar
Russian Ruble
South Korean Won
United Arab Emirates Dirham
Offshore Chinese Yuan
Ghanaian Cedi
Hungarian Forint
Albanian Lek
Brazilian Real
Singapore Dollar
Qatari Riyal
Jordanian Dinar
People:
Donald Trump
Elon Musk
Warren Buffett
Sergey Brin
Larry Page
Goldman Sachs
Kelvin Taylor
Carsten Fritsch
Christopher Chandler
Scott Bessent
Martin Schlegel
Jerome Powell
Kubra Khan
Joe Biden
Volkmar Baur
Christopher Wallerstedt
Brian Moynihan
Airlangga Hartarto
Francesco Gaetano Caltagirone
Leonardo Del Vecchio